Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1J01GB01----[1] 299 💬
2J05A F01----[1] 135 💬
3J05AG04----[1] 18 💬
4J07AH07----[1] 14 💬
5J1081----[1] 56 💬
6J695----[1] 96 💬
7J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0----[1] 96 💬
8JAK 3----[1] 46 💬
9JAK 3 Ritlecitinib----[1] 46 💬
10JAK inhibitor----[2] 46, 50 💬
11JAK1 / JAK2 Inhibitor----[1] 46 💬
12JAK1 / JAK2 Inhibtor----[1] 46 💬
13JAKi----[1] 46 💬
14Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets[1] Acetylcysteine[1] Acetylcysteine 💬--[1] 85 💬
15Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets[1] Acetylcysteine[1] Acetylcysteine 💬--[1] 85 💬
16Jaktinib Hydrochloride Tablets----[1] 271 💬
17Janus Kinase Inhibitor----[2] 46, 97 💬
18Jardiance[1] Empagliflozin[1] Empagliflozin 💬[1] SLC5A2 💬-[1] 65 💬
19JBT-101----[4] 49, 50, 51, 299 💬
20JBT-101 (lenabasum)----[1] 299 💬
21JBT101----[1] 299 💬
22Jevity 1.0----[1] 2 💬
23Jevity 1.5----[1] 2 💬
24JHL1101----[1] 46 💬
25Jianpixiaozhong particles and Wuse Dietotherapy----[1] 222 💬
26Jinarc[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
27JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
28JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
29JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
30JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
31JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
32Jinarc - Tolvaptan tablets[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
33Jinarc 15 mg tablets, Jinarc 45 mg tablets[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
34Jinarc 30 mg Tablet[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
35Jinarc 30 mg tablets, 90 mg tablets[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
36Jinarc 30 mg tablets, Jinarc 60 mg tablets[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
37Jinarc® 15mg Tablet[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
38Jinarc® 30 Tablet[1] Tolvaptan[1] Tolvaptan 💬[1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67 💬
39Jintropin AQ----[1] 78 💬
40JKB-122----[1] 95 💬
41JKB-122 in capsule or tablet form----[1] 95 💬
42JM----[2] 6, 13 💬
43JM-010----[1] 6 💬
44JM-4----[1] 13 💬
45JNJ 38518168----[1] 46 💬
46JnJ 54767414----[1] 28 💬
47JNJ-16240159-AAC----[1] 46 💬
48JNJ-31001074----[1] 6 💬
49JNJ-38518168----[1] 46 💬
50JNJ-38518168 (10 mg)----[1] 46 💬
51JNJ-38518168 (3 mg)----[1] 46 💬
52JNJ-38518168 (30 mg)----[1] 46 💬
53JNJ-38518168 / MTX----[1] 46 💬
54JNJ-38518168 50-mg Over Encapsulated Tablet----[1] 46 💬
55JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg----[1] 46 💬
56JNJ-38518168-ZBQ----[1] 46 💬
57JNJ-38518168-ZBQ - film-coated tablet - 10 mg----[1] 46 💬
58JNJ-38518168-ZBQ - film-coated tablet - 10mg----[1] 46 💬
59JNJ-38518168-ZBQ - film-coated tablet - 3 mg----[1] 46 💬
60JNJ-38518168-ZBQ - film-coated tablet - 30 mg----[1] 46 💬
61JNJ-38518168-ZBQ - film-coated tablet - 30mg----[1] 46 💬
62JNJ-38518168-ZBQ - film-coated tablet - 3mg----[1] 46 💬
63JNJ-39039039----[1] 210 💬
64JNJ-39758979----[1] 46 💬
65JNJ-39758979 (10 mg)----[1] 46 💬
66JNJ-39758979 (100 mg)----[1] 46 💬
67JNJ-39758979 (30 mg)----[1] 46 💬
68JNJ-39758979 (300 mg)----[1] 46 💬
69JNJ-39758979 / MTX----[1] 46 💬
70JNJ-39758979-AAC - enteric coated tablet - 10 mg----[1] 46 💬
71JNJ-39758979-AAC - enteric coated tablet - 100 mg----[1] 46 💬
72JNJ-39758979-AAC - enteric coated tablet - 30 mg----[1] 46 💬
73JNJ-40346527[1] JNJ-40346527---[2] 46, 96 💬
74JNJ-40346527-AAC[1] JNJ-40346527---[1] 96 💬
75JNJ-40346527-AAC - capsule - 50 mg[1] JNJ-40346527---[1] 46 💬
76JNJ-42160443----[1] 226 💬
77JNJ-54767414----[2] 28, 49 💬
78JNJ-54781532 150 mg once daily----[1] 97 💬
79JNJ-54781532 25 mg once daily----[1] 97 💬
80JNJ-54781532 75 mg once daily----[1] 97 💬
81JNJ-54781532 75 mg twice daily----[1] 97 💬
82JNJ-54781532-AAD-10 mg----[1] 97 💬
83JNJ-54781532-AAD-30 mg----[1] 97 💬
84JNJ-54781532-AAD-5 mg----[1] 97 💬
85JNJ-55920839----[1] 49 💬
86JNJ-56022473----[1] 49 💬
87JNJ-64304500----[1] 96 💬
88JNJ-64304500-AAA----[1] 96 💬
89JNJ-64841829----[1] 97 💬
90JNJ-64841842----[1] 97 💬
91JNJ-64841855----[1] 97 💬
92JNJ-64841894----[1] 97 💬
93JNJ-64841907----[1] 97 💬
94JNJ-64841920----[1] 97 💬
95JNJ-64841933----[1] 97 💬
96JNJ-64841946----[1] 97 💬
97JNJ-66525433----[1] 97 💬
98JNJ-67484703----[1] 46 💬
99JNJ-67864238----[1] 96 💬
100JNJ-67896049----[1] 86 💬
101JNJ-67896049 (ACT-293987)----[1] 86 💬
102JNJ-67896062 / ACT-064992----[2] 86, 88 💬
103JNJ-67896062/ ACT-064992----[2] 86, 88 💬
104JNJ-67896062/ACT-064922----[1] 86 💬
105JNJ-67896153/ACT-128800----[1] 13 💬
106JNJ-72537634----[1] 97 💬
107JNJ-78934804----[2] 96, 97 💬
108JNJ-80202135----[4] 11, 46, 49, 53 💬
109JNJ31-31001074----[1] 6 💬
110Joint puncture----[1] 107 💬
111Jojoba oil[1] Jojoba oil---[1] 36 💬
112Jojoba oil with broccoli sprout extract[2] Broccoli,
Jojoba oil		---[1] 36 💬
113Jorveza[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
114Jorveza 0.5 mg compresse orodispersibili[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
115Jorveza 0.5 mg orodispersible tablets[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
116Jorveza 1 mg compresse orodispersibili[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
117Jorveza 1 mg orodispersible tablets[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
118JP 1730----[1] 6 💬
119JP-1730/F01----[2] 6, 17 💬
120JP-1730/F02----[2] 6, 17 💬
121JP-1730/F03----[2] 6, 17 💬
122JR-141----[1] 19 💬
123JR-141 or Idursulfase[1] Idursulfase[1] Idursulfase 💬[1] IDS 💬[3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬[1] 19 💬
124JR-171 (lepunafusp alfa)----[1] 19 💬
125JS002----[1] 79 💬
126JS005----[1] 271 💬
127JSP191----[2] 65, 285 💬
128JTE-051----[1] 46 💬
129JTT-251----[1] 86 💬
130Juanbi pill----[1] 46 💬
131Juvit D3----[1] 6 💬
132Jyseleca[1] Filgotinib[1] Filgotinib 💬[1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46 💬
133Jyseleca 100 mg film-coated tablets[1] Filgotinib[1] Filgotinib 💬[1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46 💬
134Jyseleca 200 mg film-coated tablets[1] Filgotinib[1] Filgotinib 💬[1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46 💬
135JZP-110----[1] 6 💬